Fresenius Medical Care AG & Co. (NYSE:FMS) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) have been assigned a consensus recommendation of “Hold” from the twelve research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $53.05.

A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. restated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research report on Thursday, August 29th. Zacks Investment Research lowered shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “sell” rating and set a $41.00 price target for the company. in a research report on Monday, July 1st. Barclays upgraded shares of Fresenius Medical Care AG & Co. from an “equal weight” rating to an “overweight” rating and set a $40.23 price target for the company in a research report on Thursday, June 20th. DZ Bank restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research report on Tuesday, July 30th. Finally, Royal Bank of Canada restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, August 19th.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Morgan Stanley grew its position in Fresenius Medical Care AG & Co. by 53.3% in the second quarter. Morgan Stanley now owns 1,850,796 shares of the company’s stock worth $72,700,000 after acquiring an additional 643,494 shares in the last quarter. Marshall Wace North America L.P. grew its position in Fresenius Medical Care AG & Co. by 483.6% in the first quarter. Marshall Wace North America L.P. now owns 127,636 shares of the company’s stock worth $5,174,000 after acquiring an additional 105,765 shares in the last quarter. Marshall Wace LLP grew its position in Fresenius Medical Care AG & Co. by 58.5% in the first quarter. Marshall Wace LLP now owns 159,642 shares of the company’s stock worth $6,470,000 after acquiring an additional 58,904 shares in the last quarter. Citigroup Inc. grew its position in Fresenius Medical Care AG & Co. by 773.8% in the first quarter. Citigroup Inc. now owns 59,811 shares of the company’s stock worth $2,425,000 after acquiring an additional 52,966 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC purchased a new position in Fresenius Medical Care AG & Co. in the second quarter worth $1,095,000. Hedge funds and other institutional investors own 1.48% of the company’s stock.

FMS stock traded down $0.09 during midday trading on Wednesday, reaching $32.35. 1,661 shares of the company’s stock traded hands, compared to its average volume of 127,096. The company has a 50-day moving average price of $33.79 and a two-hundred day moving average price of $37.55. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.76 and a current ratio of 0.99. Fresenius Medical Care AG & Co. has a 52 week low of $30.99 and a 52 week high of $51.74. The firm has a market capitalization of $19.41 billion, a PE ratio of 14.20, a price-to-earnings-growth ratio of 2.30 and a beta of 1.46.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its quarterly earnings results on Tuesday, July 30th. The company reported $0.52 EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.03). The firm had revenue of $4.88 billion for the quarter, compared to analysts’ expectations of $4.78 billion. Fresenius Medical Care AG & Co. had a net margin of 7.34% and a return on equity of 10.18%. As a group, analysts predict that Fresenius Medical Care AG & Co. will post 2.38 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Read More: Most Active Stocks

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.